Novel oral anticoagulants in peripheral arterial and coronary artery disease

Area of Science:

• Cardiovascular Medicine
• Vascular Biology
• Pathology

Background:

• Atherosclerosis is a chronic arterial disease characterized by the buildup of inflammatory cells, lipids, and smooth muscle cells in the vascular intima.
• This process forms fibro-inflammatory lipid plaques, developing progressively over decades.
• Antiplatelet and anticoagulant agents are crucial in preventing atherothrombosis, a major complication.

Purpose of the Study:

• To explore the role of antiplatelet and anticoagulant therapies in the primary and secondary prevention of atherothrombosis.
• To reconsider the combination of antiplatelet and anticoagulant therapy in light of new oral anticoagulants.
• To understand the mechanisms underlying atherosclerotic plaque rupture and subsequent thrombosis.

Main Methods:

• Review of existing clinical trials and literature on antiplatelet and anticoagulant agents.
• Analysis of the pathogenesis of atherosclerotic plaque formation and rupture.
• Evaluation of the efficacy and safety of combined antithrombotic strategies.

Main Results:

• Atherosclerotic plaque rupture and thrombosis involve the activation of platelets and coagulation factors.
• The combination of antiplatelet and anticoagulant therapy is being reconsidered for secondary prevention.
• Newly developed oral anticoagulants offer potential new avenues for treatment.

Conclusions:

• Atherosclerosis is a complex fibro-inflammatory disease requiring multifaceted prevention strategies.
• Combined antiplatelet and anticoagulant therapy shows promise, particularly for secondary prevention of atherothrombosis.
• Advances in anticoagulant medications warrant further investigation into optimized treatment regimens.